Photocure ASA's (OSE: PHO) results for the third quarter and first nine months 2012 will be presented at Shippingklubben, Oslo, Norway, today at 15:00 pm CET by the President and CEO Kjetil Hestdal and CFO Erik Dahl. The presentation will be transferred live via webcast
Please find the presentation enclosed.
For more information, please contact:
PhotocurePresident & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: email@example.com
CFO Erik Dahl
Tel: +47 450 55 000, e-mail: firstname.lastname@example.org
Mary Clark, Amber Bielecka, Hollie Vile
Tel: +44 207920 2361, Email: email@example.com
About Photocure ASA
Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology(TM) platform, Photocure develops and commercializes highly selective and effective solutions within disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal cancer and skin conditions. Our aim is to provide solutions which can improve health outcomes for patients worldwide. Photocure is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at www.photocure.com.
All trademarks mentioned in this release are protected by law and registered trademarks of Photocure ASA.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Presentation 3rd quarter 2012
--This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Photocure ASA via Thomson Reuters ONEHUG#1652736